Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr 17:7:619-25.
doi: 10.2147/OTT.S46200. eCollection 2014.

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo

Cristina Raimondi  1 , Angela Gradilone  1 , Giuseppe Naso  2 , Enrico Cortesi  2 , Paola Gazzaniga  1
Affiliations
Review

Clinical utility of circulating tumor cell counting through CellSearch(®): the dilemma of a concept suspended in Limbo

Cristina Raimondi et al. Onco Targets Ther. .

Abstract

To date, 10 years after the first demonstration of circulating tumor cells (CTCs), prognostic significance in metastatic breast cancer using the US Food and Drug Administration-cleared system CellSearch(®), the potential utility of CTCs in early clinical development of drugs, their role as a surrogate marker of response to therapy, and their molecular analysis for patient stratification for targeted therapies are still major unsolved questions. Great expectations are pinned on the ongoing interventional trials aimed to demonstrate that CTCs might be of value for guiding treatment of patients and predicting cancer progression. To fill the gap between theory and practice with regard to the clinical utility of CTCs, a bridge is needed, taking into account innovative design for clinical trials, a revised definition of traditional CTCs, next-generation CTC technology, the potential clinical application of CTC analysis in non-validated settings of disease, and finally, expanding the number of patients enrolled in the studies. In this regard, the results of the first European pooled analysis definitely validated the independent prognostic value of CTC counting in metastatic breast cancer patients.

Keywords: CTC; clinical trials; prognosis.

PubMed Disclaimer

References

    1. Cristofanilli M, Budd GT, Ellis MJ, et al. CTC, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–791. - PubMed
    1. Bidard FC, Fehm T, Ignatiadis M, et al. Clinical application of CTC in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32(1–2):179–188. - PMC - PubMed
    1. SABCS.org [homepage on the Internet] The San Antonio Breast Cancer Symposium. Dec, 2013. [Accessed February 21, 2014]. Available from: http://www.sabcs.org.
    1. Fehm T, Müller V, Aktas B, et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat. 2010;124(2):403–412. - PubMed
    1. Pestrin M, Bessi S, Puglisi F, et al. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive CTC. A proof-of-concept study. Breast Cancer Res Treat. 2012;134(1):283–289. - PubMed

LinkOut - more resources